The company has a market cap of $6,303.55, a price-to-earnings ratio of 4.72, a price-to-earnings-growth ratio of 0.38 and a beta of -0.32. About 8.11 million shares traded. (NYSE:VRX). Hbk Investments L P holds 0.03% in Valeant Pharmaceuticals International, Inc.
The company's earnings per share shows growth of -11.20% for the current year and expected to arrive earnings growth for the next year at 36.58%. Valeant Pharmaceuticals International has a twelve month low of $8.31 and a twelve month high of $24.43. The company has Relative Strength Index (RSI 14) of 77.50 along with Average True Range (ATR 14) of 0.78. About 8.13 million shares traded. Forward P/E of Valeant Pharmaceuticals International, Inc.is standing at 5.33. The stock outperformed the S&P500 by 30.45%. Wells Fargo reiterated a "sell" rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, March 20th.
Earnings per Share Details of Valeant Pharmaceuticals International, Inc.: The EPS of VRX is strolling at 4.07, measuring its EPS growth this year at 158.6 percent. Vertex One Asset Management Inc. owned approximately 0.14% of Valeant Pharmaceuticals International worth $7,982,000 at the end of the most recent reporting period. (VRX). A frequently used tool among technical stock analysts is the moving average. Schroder Investment Management Group boosted its position in Valeant Pharmaceuticals International by 2,951.5% during the 4th quarter. On Tuesday, March 13 the insider PAPA JOSEPH C bought $481,500.
Start from its liquidities ratios, and the co has current ratio of 0.90 that indicates if CTL lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Its down 0.02, from 0.99 in 2017Q3. It worsened, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%.
Over the past three years Valeant has lost more than 90 percent of its market value when the company was trading at $257.53 in the summer of 2015. Oppenheimer And invested 0.02% in Valeant Pharmaceuticals International, Inc. 38,014 are held by Northwestern Mutual Wealth Mngmt Com.
Gulf Int National Bank (Uk) Ltd stated it has 98,923 shares.
Meanwhile, the issue with Valeant's relationship to now-defunct specialty pharmacy Philidor is playing out in court at the trial of former executives accused of enriching themselves at the expense of shareholders. (NYSE:VRX) for 17,054 shares. Continental Advsr Limited Liability Corporation owns 154,100 shares. This morning though Valeant Investors seem to be happy with Papa's latest moves. (NYSE:VRX) or 175,800 shares. Commerzbank Aktiengesellschaft Fi reported 660,981 shares. Gramercy Funds has 0.09% invested in Valeant Pharmaceuticals International, Inc. Cantor Fitzgerald maintained Valeant Pharmaceuticals International, Inc. The positive are 15%. The rating has been revealed in an analyst report on Tuesday, 8 May. We can assess whether Valeant Pharmaceuticals International is fuelling ROE by excessively raising debt.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Wednesday, February 28th. Also, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, March 8th. On Monday, December 4 the firm earned "Hold" rating by BTIG Research. The firm has "Neutral" rating by Nomura given on Wednesday, March 16.
A total of 13 analysts rate Valeant Pharma (NYSE:VRX) as follows: 2 "Buy", 7 "Hold" and 4 "Sell". The return on investments have been 12.50%, while the return on assets have also been 2.00%. The stock has "Hold" rating by H.C. Wainwright on Thursday, November 9. On Friday, April 6 the stock rating was upgraded by Mizuho to "Hold". The firm has "Underweight" rating given on Monday, October 16 by Morgan Stanley. Market capitalization is just a fancy declare for a comprehensible concept: it is the market value of a company's outstanding shares.
Total revenues fell 5.4 percent to $1.96 billion. He also holds an MBA from Penn State University He has two daughter and two children. 231.12 million shares or 0.22% more from 230.60 million shares in 2017Q3 were reported. (NYSE:OMC). D E Shaw Inc accumulated 251,449 shares or 0.03% of the stock. Guggenheim Ltd invested in 0% or 18,384 shs. Raymond James & Assocs has invested 0.08% in Omnicom Group Inc.